GSK's B7-H3 ADC gets FDA Breakthrough Therapy Designation
Ticker: GLAXF · Form: 6-K · Filed: Aug 20, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Aug 20, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: FDA, drug-designation, oncology
TL;DR
FDA grants GSK's B7-H3 ADC Breakthrough Therapy status for SCLC.
AI Summary
GSK plc announced on August 20, 2024, that its B7-H3-targeted antibody-drug conjugate has received Breakthrough Therapy Designation from the US FDA. This designation is for the treatment of patients with relapsed or refractory extensive-stage small-cell lung cancer.
Why It Matters
This FDA designation could expedite the development and review process for GSK's new cancer therapy, potentially bringing a new treatment option to patients with limited existing options.
Risk Assessment
Risk Level: low — This is a positive regulatory announcement regarding a drug candidate, not a financial event with immediate negative implications.
Key Players & Entities
- GSK plc (company) — Registrant
- US FDA (company) — Regulatory agency granting designation
- B7-H3-targeted antibody-drug conjugate (drug_candidate) — Therapeutic agent
- relapsed or refractory extensive-stage small-cell lung cancer (disease) — Indication for the drug
- August 20, 2024 (date) — Date of announcement
FAQ
What is the specific drug candidate that received the Breakthrough Therapy Designation?
The drug candidate is GSK's B7-H3-targeted antibody-drug conjugate.
Which regulatory body granted the Breakthrough Therapy Designation?
The United States Food and Drug Administration (US FDA) granted the designation.
What type of cancer is this designation for?
The designation is for relapsed or refractory extensive-stage small-cell lung cancer.
When was this announcement made?
The announcement was made on August 20, 2024.
What is the significance of a Breakthrough Therapy Designation?
A Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions, indicating that preliminary clinical evidence has shown that the drug may demonstrate substantial improvement over available therapy.
Filing Stats: 1,049 words · 4 min read · ~3 pages · Grade level 15.9 · Accepted 2024-08-20 06:30:47
Filing Documents
- a0178b.htm (6-K) — 39KB
- 0001654954-24-010924.txt ( ) — 40KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: August 20, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc